Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study

Neuropsychiatric Disease and Treatment

Volumn 13, Issue , 2017, Pages 2021-2035

  Durgam, Suresh ^a   Landbloom, Ronald P ^b   Mackle, Mary ^b   Wu, Xiao ^a   Mathews, Maju ^c   Nasrallah, Henry A ^d  

^a ALLERGAN INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asenapine; Long term; Olanzapine; Safety; Schizophrenia; Weight

Indexed keywords

ASENAPINE; CREATINE KINASE; INSULIN; OLANZAPINE;

ADULT; ADVERSE OUTCOME; AKATHISIA; ARTICLE; CHRONIC BRONCHITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATITIS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERSOMNIA; HYPERTENSION; HYPESTHESIA; INCIDENCE; INSOMNIA; INSULIN BLOOD LEVEL; LONG TERM CARE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STUDY DESIGN; SUICIDE ATTEMPT; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT CHANGE;

EID: 85026806966     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S130211     Document Type: Article

References (27)

1. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005; 66(2):183-194.
2. Palmer BA, Pankratz V, Bostwick J. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3): 247-253.
3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4: clinical features and conceptualization. Schizophr Res. 2009;110(1-3): 1-23.
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
5. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268-274.
6. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
7. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106-115.
8. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-1500.
9. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349-355.
10. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
11. Landbloom R, Mackle M, Wu X, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. Epub 2016 Nov 8.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision. Washington: APA; 2000.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Heath; 1976.
14. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
15. Guy W. The Abnormal Movement Scale. In: ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Heath; 1976:218-222.
16. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
18. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138-146.
19. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014;75(3):238-245.
20. Orr C, Deshpande S, Sawh S, Jones PM, Vasudev K. Asenapine for the treatment of psychotic disorders: a systematic review and meta-analysis. Can J Psychiatry. 2017;62(2):123-137.
21. Riordan HJ, Antonini P, Murphy MF. Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. Am Health Drug Benefits. 2011; 4(5):292-302.
22. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
23. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res. 2008;101(1-3): 273-286.
24. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68 Suppl 1:20-27.
25. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008; 69 Suppl 1:32-44.
26. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196-203.
27. Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13(6):803-830.